Novavax approved in EU as fifth vaccine effective against COVID-19

The European Union’s medicines regulator has approved a new coronavirus vaccine made by US biotech company Novavax. It’s the fifth jab to be greenlighted for use within the EU – for those 18 and above. The regulator said trial data showed the Novavax jab had no serious side effects. It requires two doses, three weeks apart. It showed high effectiveness against older coronavirus variants – but it is unclear how it will perform against Omicron. Novavax uses an older protein-based technology, raising hopes it can convince people who are hesitant about taking the newer mRNA vaccines.